Wall Street analysts expect Steris PLC (NYSE:STE) to announce sales of $673.53 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Steris’ earnings, with the lowest sales estimate coming in at $669.10 million and the highest estimate coming in at $676.10 million. Steris reported sales of $638.76 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.4%. The company is expected to report its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Steris will report full-year sales of $2.94 billion for the current financial year. For the next fiscal year, analysts anticipate that the company will report sales of $3.10 billion, with estimates ranging from $3.09 billion to $3.11 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Steris.
Steris (NYSE:STE) last issued its quarterly earnings data on Monday, May 13th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.09. The firm had revenue of $768.00 million during the quarter, compared to the consensus estimate of $738.87 million. Steris had a return on equity of 13.34% and a net margin of 10.93%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.24 EPS.
Several equities analysts have recently commented on STE shares. Zacks Investment Research raised shares of Steris from a “sell” rating to a “hold” rating in a research note on Thursday, March 28th. Stephens reaffirmed a “buy” rating and issued a $135.00 target price on shares of Steris in a research report on Thursday, February 14th. JMP Securities reaffirmed a “buy” rating and issued a $135.00 target price on shares of Steris in a research report on Thursday, February 14th. Finally, KeyCorp increased their target price on Steris from $135.00 to $138.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 15th. Five analysts have rated the stock with a buy rating, Steris has a consensus rating of “Buy” and an average price target of $148.20.
In other Steris news, Director Mohsen Sohi sold 3,133 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $135.94, for a total transaction of $425,900.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Walter M. Rosebrough, Jr. sold 50,000 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $125.00, for a total value of $6,250,000.00. Following the sale, the chief executive officer now owns 98,895 shares of the company’s stock, valued at $12,361,875. The disclosure for this sale can be found here. Insiders sold a total of 60,351 shares of company stock valued at $7,592,622 in the last quarter. 2.38% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund boosted its position in Steris by 10,585.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 3,572,743 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 3,539,306 shares during the period. Advisory Services Network LLC boosted its position in Steris by 26.0% during the 4th quarter. Advisory Services Network LLC now owns 427 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 88 shares during the period. Executive Wealth Management LLC acquired a new stake in Steris during the 4th quarter worth about $47,000. Pinebridge Investments L.P. acquired a new stake in Steris during the 1st quarter worth about $50,000. Finally, Enlightenment Research LLC acquired a new stake in Steris during the 4th quarter worth about $53,000. Hedge funds and other institutional investors own 82.81% of the company’s stock.
Shares of NYSE:STE traded down $1.37 during midday trading on Monday, hitting $134.74. 10,422 shares of the stock traded hands, compared to its average volume of 531,826. The company has a market cap of $11.49 billion, a price-to-earnings ratio of 27.54 and a beta of 1.06. The company has a current ratio of 2.27, a quick ratio of 1.82 and a debt-to-equity ratio of 0.37. Steris has a one year low of $99.14 and a one year high of $137.60.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Wednesday, June 12th will be given a $0.34 dividend. The ex-dividend date of this dividend is Tuesday, June 11th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.01%. Steris’s dividend payout ratio (DPR) is 27.81%.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
See Also: Hedge Funds – How They Work For Investors
Get a free copy of the Zacks research report on Steris (STE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.